{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=5",
    "query": {
      "condition": "Adenosine",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 152,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T18:00:28.276Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06092346",
      "title": "A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AMPD3, OMIM*102772, AMP Deaminase Deficiency",
        "AK1, OMIM *103000, Adenylate Kinase Deficiency",
        "AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency",
        "TPMT, OMIM *187680, Thoipurines, Poor Metabolism of",
        "IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11",
        "APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency",
        "HPRT1, OMIM *308000 Lesch-Nyhan Disease",
        "XDH, OMIM *607633, Xanthinuria Type 1",
        "SLC2A9, OMIM *606142 Hypouricemia",
        "SLC22A12, OMIM *607096 Hypouricemia",
        "PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease",
        "PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity",
        "AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia",
        "ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35",
        "ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency",
        "PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency",
        "ADA2, OMIM *607575,Sneddon Syndrome; VAIHS",
        "CAD, *1140120, Developmental and Epileptic Encephalopathy",
        "UPB1, OMIM *606673, Beta-ureidopropionase Deficiency",
        "DPYS, OMIM *613326, Dihydropyrimidinase Deficiency",
        "DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency",
        "DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)",
        "UMPS, OMIM *613891, Orotic Aciduria",
        "NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency",
        "UNG, OMIM *191525, Hyper-IgM Syndrome 5",
        "AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2",
        "Purine-Pyrimidine Metabolism",
        "Metabolic Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Month to 100 Years"
      },
      "enrollment_count": 999,
      "start_date": "2023-12-19",
      "completion_date": "2099-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06092346"
    },
    {
      "nct_id": "NCT01088503",
      "title": "Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "ADP receptor inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12227,
      "start_date": "2010-03",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 185,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fayetteville",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088503"
    },
    {
      "nct_id": "NCT02509546",
      "title": "8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "8-Chloroadenosine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-10-05",
      "completion_date": "2021-03-16",
      "has_results": true,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02509546"
    },
    {
      "nct_id": "NCT04306900",
      "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "TTX-030, budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab and docetaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and budigalimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030 and pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "TTX-030, nab-paclitaxel and gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Budigalimab and mFOLFOX6",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Trishula Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 185,
      "start_date": "2020-03-30",
      "completion_date": "2024-03-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306900"
    },
    {
      "nct_id": "NCT02226276",
      "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bone Metastases",
        "HER2-positive Breast Cancer",
        "Liver Metastases",
        "Lung Metastases",
        "Recurrent Breast Cancer",
        "Soft Tissue Metastases",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "fludeoxyglucose F 18",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "copper Cu 64-DOTA-trastuzumab",
          "type": "RADIATION"
        },
        {
          "name": "ado-trastuzumab emtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2015-02-25",
      "completion_date": "2027-09-07",
      "has_results": true,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02226276"
    },
    {
      "nct_id": "NCT02655016",
      "title": "A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 733,
      "start_date": "2016-07-11",
      "completion_date": "2026-05-29",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 47,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02655016"
    },
    {
      "nct_id": "NCT05898399",
      "title": "Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ART6043",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artios Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 181,
      "start_date": "2023-06-30",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 7,
      "location_summary": "Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05898399"
    },
    {
      "nct_id": "NCT00208299",
      "title": "ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Adenosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1231,
      "start_date": "2003-10",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2009-11-26",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00208299"
    },
    {
      "nct_id": "NCT03326193",
      "title": "A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 105,
      "start_date": "2017-12-12",
      "completion_date": "2024-07-12",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 29,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03326193"
    },
    {
      "nct_id": "NCT05501054",
      "title": "Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ciforadenant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-02-09",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-04T18:00:28.276Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501054"
    }
  ]
}